NIH R01 · 2025
PROJECT SUMMARY The development of neoantigen cancer vaccines is transforming cancer immunotherapy – providing an approach to stimulate pre-existing and de novo anti-tumor T cell responses. These vaccines are designed to introduce tumor-specific neoantigens to activate the immune system, and can be amplified through tumor lysis–mediated epitope spreading. The focus of this project is to improve the therapeutic efficacy and safety of microbial neoantigen vaccines by modulating both their localization and persistence within the tumor microenvironment. Microbial vectors, such as E. coli Nissle 1917, have the natural ability to target hypoxic, immunosuppressed regions within tumors and deliver…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.